Company Insight – Page 30 – media

Roche out-licneses lebrikizumab to Dermira

Roche has agreed to out-license certain rights to its invesitgational atropic dermatitis drug lebrikizumab to Demira in a deal that could be worth more than $1.4 billion.
- Source: pharmatimes
- 454
- August 10, 2017
Company Insight dermatitis Dermira lebrikizumab Market Views
Kite begins EU trial of CAR–T therapy

Kite Pharma has begun treating the first EU patients with its investigational CAR–T candidate, axicabtagene ciloleucel (axi-cel), in the safety expansion cohort of the ZUMA-1 trial.
- Source: pharmatimes
- 867
- August 10, 2017
CAR–T Clinical Trials Company Insight EU FDA
NICE backs new treatment option for psoriasis

The National Institute for Health and Care Excellence has issued draft guidelines backing NHS use of Almirall’s Skilarence to treat moderate to severe plaque psoriasis.
- Source: pharmatimes
- 530
- August 9, 2017
Company Insight New Approvals NHS NICE psoriasis
In2Bones wins FDA nod for 2 foot repair systems

In2Bones said today that its US subsidiary received FDA clearance for its 5MS Fracture repair and CoLag locking compression screw systems.
- Source: massdevice.com
- 646
- August 9, 2017
Company Insight deformities fracture New Approvals system
RealView integrates Intel RealSense technology into AR medical system

RealView Imaging has integrated the Intel RealSense SR300-Series camera into its holographic augmented reality (AR) medical system, Holoscope-i.
- Source: medicaldevices-network.com
- 630
- August 8, 2017
AR Company Insight medical
Researchers demonstrate potential of new PET tracer for imaging prostate cancer

In the featured translational article in the August issue of The Journal of Nuclear Medicine, researchers at the University of Michigan demonstrate the potential of a new PET tracer, Carbon-11 labeled sarcosine (11C-sarcosine), for imaging prostate cancer, and set the stage for its possible use in monitoring other cancers.
- Source: news-medical.net
- 551
- August 8, 2017
cancer Company Insight PET prostate tracer
Fortimedix launches short instruments for SymphonX single-port platform

Fortimedix Surgical said today it launched a shorter set of instruments for its SymphonX single-port surgical platform in the US.
- Source: Massdevice
- 548
- August 8, 2017
Company Insight instrument microlaparoscopic surgical
FDA extends review on Dynavax’s Heplisav-B

FDA extends review on Dynavax's hepatitis B vaccine candidate Heplisav-B, but both management and analysts said they remain confident in approval.
- Source: fiercepharm
- 632
- August 7, 2017
Company Insight FDA hepatitis Heplisav-B Market Views vaccine
CombiMatrix, Skyline Medical, Victory Square Technologies

The merger and acquisition information of CombiMatrix, Skyline Medical and Victory Square Technologies.
- Source: medicaldevices-network.com
- 392
- August 7, 2017
Company Insight M&A Market Views
Roche reports strong performance in the first half of 2017

Commenting on the Group’s results, Roche CEO Severin Schwan said: “In the first half of the year, both our Pharmaceuticals and Diagnostics Divisions showed strong performance, very much driven by new product launches. Particularly pleasing is the very successful launch of Ocrevus for the treatment of two forms of multiple sclerosis. Based on our half-year performance, we raised the outlook for the full-year to mid-single digit sales growth.”
- Source: www.roche.com
- 522
- August 4, 2017
Company Insight

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.